Glenio Bitencourt Mizubuti

Glenio Bitencourt Mizubuti

Auto-generated profile, based on publicly available information

Glenio Bitencourt Mizubuti

Queen’s University, Kingston, Ontario, Canada

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2023 in Journal of Clinical Anesthesia
Verified
Journal Article
Closed access
SSSaullo Queiroz Silveira
Saullo Queiroz Silveira
LSLeopoldo Muniz da Silva
Leopoldo Muniz da Silva
AAArthur de Campos Vieira Abib
Arthur de Campos Vieira Abib
DMDiogo Turiani Hourneaux de Moura
Diogo Turiani Hourneaux de Moura
EMEduardo Guimarães Hourneaux de Moura
Eduardo Guimarães Hourneaux de Moura
GMGlenio B. Mizubuti
Glenio B. Mizubuti

1 May 2018 in Anesthesia & Analgesia
Verified
Journal Article
Closed access
AHAnthony M. H. Ho
Anthony M. H. Ho
RPRachel Phelan
Rachel Phelan
GMGlenio B. Mizubuti
Glenio B. Mizubuti
JMJohn A. C. Murdoch
John A. C. Murdoch
SWSarah Wickett
Sarah Wickett
IGIan Gilron
Ian Gilron
Before–after study designs are effective research tools and in some cases, have changed practice. These designs, however, are inherently susceptible to bias (ie, systematic errors) that are sometimes subtle but can invalidate their conclusions. This overview provides examples of before–after studies relevant to anesthesiologists to illustrate potential sources of bias, including selection/assignment, history, regression to the mean, test–retest, maturation, observer, retrospective, Hawthorne, instrumentation, attrition, and reporting/publication bias. Mitigating strategies include using a control group, blinding, matching before and after cohorts, minimizing the time lag between cohorts, using prospective data collection with consistent measuring/reporting criteria, time series data collection, and/or alternative study designs, when possible. Improved reporting with enforcement of the Enhancing Quality and Transparency of Health Research (EQUATOR) checklists will serve to increase transparency and aid in interpretation. By highlighting the potential types of bias and strategies to improve transparency and mitigate flaws, this overview aims to better equip anesthesiologists in designing and/or critically appraising before–after studies.

22 October 2024 in Anaesthesia
Verified
Journal Article
Open access
RNRafael S. F. Nersessian
Rafael S. F. Nersessian
LSLeopoldo M. da Silva
Leopoldo M. da Silva
MCMarco Aurélio S. Carvalho
Marco Aurélio S. Carvalho
SSSaullo Q. Silveira
Saullo Q. Silveira
AAArthur C. V. Abib
Arthur C. V. Abib
GMGlenio B. Mizubuti
Glenio B. Mizubuti
Summary: Background: Semaglutide is a long‐acting glucagon‐like peptide‐1 receptor agonist known to delay gastric emptying. Despite a growing body of evidence, its peri‐operative safety profile remains uncertain, particularly with regard to the risk of increased residual gastric content and aspiration of gastric contents during anaesthesia. We hypothesised that semaglutide interruption of ≤ 10 days before elective surgical procedures is insufficient to reduce or normalise the residual gastric content, despite fasting intervals that comply with current guidelines. Methods: In this prospective observational study, we recruited patients who received pre‐operative once‐weekly subcutaneous semaglutide within 10 days of the procedure (semaglutide group) and control patients who had not been exposed to semaglutide (non‐semaglutide group). On the day of surgery, all patients underwent pre‐operative point‐of‐care gastric ultrasound to evaluate their residual gastric content. Increased residual gastric content was defined as any solid content or > 1.5 ml.kg ‐1 of clear fluids as assessed by gastric ultrasound. Results: We recruited 220 patients, 107 in the semaglutide group and 113 in the non‐semaglutide group. Increased residual gastric content was found in 43/107 patients (40%) in the semaglutide group and 3/113 (3%) in the non‐semaglutide group (p < 0.001). In propensity‐weighted analysis, semaglutide use (OR 36.97, 95%CI 16.54–99.32), age (OR 0.95, 95%CI 0.93–0.98) and male sex (OR 2.28, 95%CI 1.29–4.06) were significantly associated with increased residual gastric content. There were no cases of pulmonary aspiration of gastric contents. Conclusion: Pre‐operative semaglutide use within 10 days of elective surgical procedures was independently associated with increased risk of residual gastric content on pre‐operative gastric ultrasound assessment.

31 October 2024 in Journal of Clinical Anesthesia
Verified
Journal Article
Open access
LSLeonardo Barbosa Santos
Leonardo Barbosa Santos
GMGlenio B. Mizubuti
Glenio B. Mizubuti
LSLeopoldo Muniz da Silva
Leopoldo Muniz da Silva
SSSaullo Queiroz Silveira
Saullo Queiroz Silveira
RNRafael Souza Fava Nersessian
Rafael Souza Fava Nersessian
JVJoaquim Edson Vieira
Joaquim Edson Vieira
Recent evidence suggests that perioperative semaglutide use is associated with increased residual gastric content (RGC) and risk of bronchoaspiration under anesthesia. We compared the occurrence of increased RGC in semaglutide users and non-users undergoing esophagogastroduodenoscopy to define the time interval at which RGC becomes comparable between groups. This was a single-center retrospective electronic chart review at a tertiary hospital. Patients undergoing esophagogastroduodenoscopy under deep sedation/general anesthesia between July/2021-July/2023 were included and divided into two (SG = semaglutide, NSG = non-semaglutide) groups, according to whether they had received semaglutide within 30 days prior to the esophagogastroduodenoscopy. Univariate and multivariate logistic regression were performed to explore which factors were associated with increased RGC, defined as any amount of solid content, or > 0.8 mL/Kg (measured from the aspiration/suction canister) of fluid content. Among the 1094 (SG = 123; NSG = 971) patients included, increased RGC was observed in 56 (5.12%), being 25 (20.33%) in the SG and 31 (3.19%) in the NSG (p < 0.001). Following weighted analysis, the presence of ongoing digestive symptoms (nausea/vomiting, dyspepsia, and/or bloating/abdominal distension) pre-esophagogastroduodenoscopy [OR = 15.1 (95% confidence interval (CI) 9.85-23.45)] and the time intervals of preoperative semaglutide interruption < 8 days [OR 10.0 (95%CI 6.67-15.65)] and 8-14 days [4.59 (95%CI 2.91-7.37)] remained significantly associated with increased RGC. Following inverse probability treatment weighting adjustment including a composite variable 'time intervals of semaglutide interruption' versus 'presence of ongoing digestive symptoms', only time intervals > 14 days and without digestive symptoms showed no association with increased RGC [OR = 0.77 (95%CI 0.22-2.01)]. Perioperative semaglutide use is associated with increased RGC in patients undergoing elective esophagogastroduodenoscopy. Preoperative discontinuation of > 21 days and > 14 days in patients with and without ongoing digestive symptoms, respectively, resulted in RGC similar to non-semaglutide users.

30 January 2024 in Current Opinion in Anaesthesiology
Verified
Journal Article
Closed access
GMGlenio B. Mizubuti
Glenio B. Mizubuti
AHAnthony M.-H. Ho
Anthony M.-H. Ho
LSLeopoldo Muniz da Silva
Leopoldo Muniz da Silva
RPRachel Phelan
Rachel Phelan
Purpose of review: To summarize the mechanism of action, clinical outcomes, and perioperative implications of glucagon-like peptide-1 receptor agonists (GLP-1-RAs). Specifically, this review focuses on the available literature surrounding complications (primarily, bronchoaspiration) and current recommendations, as well as knowledge gaps and future research directions on the perioperative management of GLP-1-RAs. Recent findings: GLP-1-RAs are known to delay gastric emptying. Accordingly, recent case reports and retrospective observational studies, while anecdotal, suggest that the perioperative use of GLP-1-RAs may increase the risk of bronchoaspiration despite fasting intervals that comply with (and often exceed) current guidelines. As a result, guidelines and safety bulletins have been published by several Anesthesiology Societies. Summary: While rapidly emerging evidence suggests that perioperative GLP-1-RAs use is associated with delayed gastric emptying and increased risk of bronchoaspiration (particularly in patients undergoing general anesthesia and/or deep sedation), high-quality studies are needed to provide definitive answers with respect to the safety and duration of preoperative drug cessation, and optimal fasting intervals according to the specific GLP-1-RA agent, the dose/duration of administration, and patient-specific factors. Meanwhile, clinicians must be aware of the potential risks associated with the perioperative use of GLP-1-RAs and follow the recommendations put forth by their respective Anesthesiology Societies.

16 April 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
HLHelidea de Oliveira Lima
Helidea de Oliveira Lima
LSLeopoldo Muniz da Silva
Leopoldo Muniz da Silva
AAArthur de Campos Vieira Abib
Arthur de Campos Vieira Abib
LTLeandro Reis Tavares
Leandro Reis Tavares
DSDaniel Wagner de Castro Lima Santos
Daniel Wagner de Castro Lima Santos
GMGlenio B. Mizubuti
Glenio B. Mizubuti
COVID-19-related in-hospital mortality has been reported at 30.7–47.3% in Brazil, however studies assessing exclusively private hospitals are lacking. This is important because of significant differences existing between the Brazilian private and public healthcare systems. We aimed to determine the COVID-19-related in-hospital mortality and associated risk factors in a Brazilian private network from March/2020 to March/2021. Data were extracted from institutional database and analyzed using Cox regression model. Length of hospitalization and death-related factors were modeled based on available independent variables. In total, 38,937 COVID-19 patients were hospitalized of whom 3058 (7.8%) died. Admission to the intensive care unit occurred in 62.5% of cases, and 11.5% and 3.8% required mechanical ventilation (MV) and renal replacement therapy (RRT), respectively. In the adjusted model, age ≥ 61 years-old, comorbidities, and the need for MV and/or RRT were significantly associated with increased mortality (p < 0.05). Obesity and hypertension were associated with the need for MV and RRT (p < 0.05).